4-(2-溴乙基)-3,5-二甲基-1H-吡咯 | 83467-28-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 4-(2-溴乙基)-3,5-二甲基-1H-吡咯
• 中文别名: 4-(2-溴乙基)-3,5-二甲基-1H-吡唑
• 英文名称: 4-(2-bromoethyl)-3,5-dimethyl-1H-pyrazole
• 英文别名: 3,5-dimethyl-4-(2-bromoethyl)pyrazole；4-(2-bromo-ethyl)-3,5-dimethyl-1H-pyrazole
• CAS: 83467-28-1
• 化学式: C₇H₁₁BrN₂
• mdl: MFCD00480987
• 分子量: 203.082
• InChiKey: HGGLMDBNLJUEKA-UHFFFAOYSA-N

物化性质

• 熔点：
  127-128 °C
• 沸点：
  308.4±37.0 °C(Predicted)
• 密度：
  1.455±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2933199090

SDS

Name:	4-(2-Bromoethyl)-3 5-dimethyl-1H-pyrazole Material Safety Data Sheet
Synonym:	None Known
CAS:	83467-28-1

Section 1 - Chemical Product MSDS Name:4-(2-Bromoethyl)-3 5-dimethyl-1H-pyrazole Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
83467-28-1	4-(2-Bromoethyl)-3,5-dimethyl-1H-pyraz	97+	unlisted

Hazard Symbols: C
Risk Phrases: 34

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Causes burns.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Chronic exposure may cause effects similar to those of acute exposure.

---

Section 4 - FIRST AID MEASURES
Eyes: Get medical aid. Do NOT allow victim to rub eyes or keep eyes closed. Extensive irrigation with water is required (at least 30 minutes).
Skin:
In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Get medical aid immediately. Wash clothing before reuse.
Ingestion:
If swallowed, do NOT induce vomiting. Get medical aid immediately.
If victim is fully conscious, give a cupful of water. Never give anything by mouth to an unconscious person.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If breathing is difficult, give oxygen. Do NOT use mouth-to-mouth resuscitation. If breathing has ceased apply artificial respiration using oxygen and a suitable mechanical device such as a bag and a mask.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions. Provide ventilation. Vacuum or sweep up material and place into a suitable, dry disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Minimize dust generation and accumulation. Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing.
Keep container tightly closed. Do not ingest or inhale. Discard contaminated shoes. Use only with adequate ventilation.
Storage:
Store in a cool, dry place. Keep container closed when not in use.
Store under an inert atmosphere.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 83467-28-1: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 117.5-120 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C7H11BrN2
Molecular Weight: 203.08

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Dust generation.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, oxides of nitrogen, carbon dioxide, hydrogen bromide, bromine.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 83467-28-1 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-(2-Bromoethyl)-3,5-dimethyl-1H-pyrazole - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION
Ecotoxicity:
Fish: Pseudomonas putida:

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: CORROSIVE SOLID, N.O.S.
Hazard Class: 8
UN Number: 1759
Packing Group: III
IMO
Shipping Name: CORROSIVE SOLID, N.O.S.
Hazard Class: 8
UN Number: 1759
Packing Group: III
RID/ADR
Shipping Name: CORROSIVE SOLID, N.O.S.
Hazard Class: 8
UN Number: 1759
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 34 Causes burns.
Safety Phrases:
S 6 Keep under nitrogen.
S 22 Do not breathe dust.
S 24/25 Avoid contact with skin and eyes.
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 83467-28-1: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 83467-28-1 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 83467-28-1 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-(2-溴乙基)-3,5-二甲基-1H-吡咯 、 茚 在 正丁基锂 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 以79%的产率得到4-(2-(1H-inden-3-yl)ethyl)-3,5-dimethyl-1H-pyrazole
  参考文献：
  名称：

  Synthesis and structural characterization of (CH2)n-bridged indenyl-pyrazoles and their cyclopentadienyl nickel(II) complexes

  摘要：

  A new class of (CH2)(n)-bridged indenyl-pyrazoles [4-{Ind-(CH2)(n)}-RR'PzH] (Ind = 1H-inden-3-yl, n = 1-3, RR'Pz = 3,5-disubstituted pyrazolato) were synthesized. Reactions of the indenyl-functionalized pyrazoles with nickelocene in refluxing toluene afforded trimetallic and dimetallic cyclopentadienyl nickel(II) complexes, i.e., [CpNi{4-(Ind-(CH2)(n))-RR'Pz}(2)](2)Ni and [CpNi{4-(Ind-(CH2)(n))-RR'Pz}](2), depending on the steric hindrance from the 3,5-disubstituents on the pyrazolato rings. In the CpNi(II) complexes, pyrazolato ligands exhibit mu-eta(1): eta(1) coordination to the metal centers and the indenyl moieties demonstrate no interaction with the metals. All the indenyl-pyrazoles and their complexes were characterized by spectroscopic and analytical methods including X-ray crystallographic study. (C) 2008 Elsevier B. V. All rights reserved.

  DOI：

  10.1016/j.jorganchem.2008.10.021
• 作为产物：
  描述：

  1,1-乙酰基环丙烷 在 溴化铵 、 一水合肼 作用下， 以 水 为溶剂， 以55%的产率得到4-(2-溴乙基)-3,5-二甲基-1H-吡咯
  参考文献：
  名称：

  重排和环化—XVI：1，1-二乙酰基环丙烷与肼和羟胺衍生物的开环反应，是β-X-乙基取代的吡唑和异恶唑的新颖合成

  摘要：

  1,1-二乙酰基环丙烷（1）与许多肼和羟胺衍生物的反应通过环丙烷开环进行，并引入外部亲核试剂（溶剂），得到3,5-二甲基吡唑的4-β-X-乙基衍生物和-异恶唑，这些杂环的新途径。这种环断裂在作为溶剂的水中特别平滑地发生。讨论了这种异常温和的亲核环丙烷开环的原理。

  DOI：

  10.1016/0040-4020(82)80149-x

文献信息

• [EN] PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE PROTÉINE TYROSINE PHOSPHATASE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：CALICO LIFE SCIENCES LLC

  公开号：WO2020186199A1

  公开（公告）日：2020-09-17

  Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN 1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.

  本文提供了用于抑制蛋白酪氨酸磷酸酶的化合物、组合物和方法，例如蛋白酪氨酸磷酸酶非受体型2（PTPN2）和/或蛋白酪氨酸磷酸酶非受体型1（PTPN1），以及用于治疗对PTPN1或PTPN2抑制剂治疗有良好反应的相关疾病、紊乱和状况的方法，例如癌症或代谢性疾病。
• [EN] SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF<br/>[FR] PIPÉRIDINES SUBSTITUÉES QUI ACCROISSENT L'ACTIVITÉ DE P53, ET UTILISATIONS DE CES COMPOSÉS
  申请人：SCHERING CORP

  公开号：WO2011046771A1

  公开（公告）日：2011-04-21

  The present invention provides a compound of Formula (1) as described herein or a pharmaceutically acceptable salt, solvate or ester thereof. The compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and methods of treating cancer using the same.

  本发明提供了如下所述的化合物的化学式（1）或其药学上可接受的盐、溶剂合物或酯。这些化合物可用作HDM2蛋白的抑制剂。还公开了包含上述化合物的药物组合物以及使用它们治疗癌症的方法。
• HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES B
  申请人：SHULTZ Michael

  公开号：US20090247547A1

  公开（公告）日：2009-10-01

  The present teachings relate to compounds of Formula I: and pharmaceutically acceptable salts, hydrates, esters, and prodrugs thereof, wherein R 1 , R 2 , R 3 , Y, Z, and are as defined herein. The present teachings also provide methods of preparing compounds of Formula I and methods of using compounds of Formula I in treating, inhibiting, or preventing pathologic conditions or disorders mediated wholly or in part by deacetylases.

  目前的教导与化合物I的公式有关：及其药用盐、水合物、酯和前药，其中R1、R2、R3、Y、Z和如本文所定义的。目前的教导还提供了制备公式I化合物的方法以及使用公式I化合物治疗、抑制或预防完全或部分由去乙酰酶介导的病理状况或紊乱的方法。
• [EN] INDAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE<br/>[FR] COMPOSÉS D'INDAZOLE, COMPOSITIONS ET PROCÉDÉS D'UTILISATION
  申请人：HOFFMANN LA ROCHE

  公开号：WO2013024011A1

  公开（公告）日：2013-02-21

  A compound of formula I: stereoisomers or a pharmaceutically acceptable salt thereof, wherein X, X1, X2, X3, R1, R2, R3, R4, R5 and R6 are described herein, compositions including the compounds and methods of making and using the compounds for the treatment of diseases.

  公式I的化合物：其立体异构体或其药学上可接受的盐，其中X、X1、X2、X3、R1、R2、R3、R4、R5和R6如本文所述，包括该化合物的组合物以及用于治疗疾病的制备和使用该化合物的方法。
• [EN] ARYLOXY AND ARYLALKYLENEOXY SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES<br/>[FR] THIAZOLOQUINOLINES ET THIAZOLONAPHTYRIDINES SUBSTITUES PAR ARYLOXY ET ARYLALKYLENEOXY
  申请人：3M INNOVATIVE PROPERTIES CO

  公开号：WO2006009826A1

  公开（公告）日：2006-01-26

  Thiazoloquinoline and thiazolonaphthyridine compounds having an aryloxy or arylalkyleneoxy substituent at the 6-, 7-, 8-, or 9-position, pharmaceutical compositions containing the compounds, intermediates, and methods of making and methods of use of these compounds as immunomodulators, for modulating cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.

  本文披露了在6、7、8或9位点具有芳氧基或芳基烷氧基取代基的噻唑喹啉和噻唑萘啉化合物，含有这些化合物的药物组合物，中间体，以及制备这些化合物的方法和使用这些化合物作为免疫调节剂的方法，用于调节动物中的细胞因子生物合成，并用于治疗包括病毒性和肿瘤性疾病在内的疾病。